The cyclin-dependent kinase inhibitor 5, 6-dichloro-1-beta-D-ribofuranosylbenzimidazole induces nongenotoxic, DNA replication-independent apoptosis of normal and leukemic cells, regardless of their p53 status

BMC Cancer

Volumn 9, Issue , 2009, Pages 281-

  Turinetto, Valentina ^a   Porcedda, Paola ^a   Orlando, Luca ^a   De Marchi, Mario ^a   Amoroso, Antonio ^a   Giachino, Claudia ^a  

^a UNIVERSITY OF TURIN   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

5,6 DICHLOROBENZIMIDAZOLE RIBOSIDE; ATM PROTEIN; DNA; HISTONE H2AX; NIBRIN; PROTEIN BAX; PROTEIN P53; PROTEIN P73;

ACUTE GRANULOCYTIC LEUKEMIA; APOPTOSIS; ARTICLE; CANCER RESISTANCE; CELL SURVIVAL; CELL VIABILITY; CONTROLLED STUDY; DNA DAMAGE; DNA REPLICATION; DRUG SENSITIVITY; GENOTOXICITY; HUMAN; HUMAN CELL; LEUKEMIA; PROTEIN FUNCTION; PROTEIN PHOSPHORYLATION; RAJI CELL; T CELL LEUKEMIA;

APOPTOSIS; CELL LINE, TUMOR; CELLS, CULTURED; CYCLIN-DEPENDENT KINASES; DICHLORORIBOFURANOSYLBENZIMIDAZOLE; DNA REPLICATION; HUMANS; LEUKEMIA; LYMPHOCYTES; PROTEIN KINASE INHIBITORS; TUMOR SUPPRESSOR PROTEIN P53;

EID: 70349871086     PISSN: None     EISSN: 14712407     Source Type: Journal    
DOI: 10.1186/1471-2407-9-281     Document Type: Article

References (61)

1. Allan JM, Travis LB. Mechanisms of therapy-related carcinogenesis. Nat Rev Cancer 2005, 5:943-955. 10.1038/nrc1749, 16294218.
2. Aas T, Borresen AL, Geisler S, Smith-Sorensen B, Johnsen H, Varhaug JE, Akslen LA, Lonning PE. Specific P53 mutations are associated with de novo resistance to doxorubicin in breast cancer patients. Nat Med 1996, 2:811-814. 10.1038/nm0796-811, 8673929.
3. Elli R, Chessa L, Antonelli A, Petrinelli P, Ambra R, Marcucci L. Effects of topoisomerase II inhibition in lymphoblasts from patients with progeroid and "chromosome instability" syndromes. Cancer Genet Cytogenet 1996, 87:112-116. 10.1016/0165-4608(95)00294-4, 8625255.
4. Hsiao MH, Yu AL, Yeargin J, Ku D, Haas M. Nonhereditary p53 mutations in T-cell acute lymphoblastic leukemia are associated with the relapse phase. Blood 1994, 83:2922-2930.
5. Lane DP, Midgley CA, Hupp TR, Lu X, Vojtesek B, Picksley SM. On the regulation of the p53 tumour suppressor, and its role in the cellular response to DNA damage. Philos Trans R Soc Lond B Biol Sci 1995, 347:83-87. 10.1098/rstb.1995.0013, 7746859.
6. Lowe SW, Bodis S, McClatchey A, Remington L, Ruley HE, Fisher DE, Housman DE, Jacks T. p53 status and the efficacy of cancer therapy in vivo. Science 1994, 266:807-810. 10.1126/science.7973635, 7973635.
7. Pedersen-Bjergaard J, Philip P, Larsen SO, Jensen G, Byrsting K. Chromosome aberrations and prognostic factors in therapy-related myelodysplasia and acute nonlymphocytic leukemia. Blood 1990, 76:1083-1091.
8. Pedersen-Bjergaard J, Daugaard G, Hansen SW, Philip P, Larsen SO, Rorth M. Increased risk of myelodysplasia and leukaemia after etoposide, cisplatin, and bleomycin for germ-cell tumours. Lancet 1991, 338:359-363. 10.1016/0140-6736(91)90490-G, 1713639.
9. Pedersen-Bjergaard J, Andersen MK, Andersen MT, Christiansen DH. Genetics of therapy-related myelodysplasia and acute myeloid leukemia. Leukemia 2008, 22:240-248. 10.1038/sj.leu.2405078, 18200041.
10. Petitjean A, Mathe E, Kato S, Ishioka C, Tavtigian SV, Hainaut P, Olivier M. Impact of mutant p53 functional properties on TP53 mutation patterns and tumor phenotype: lessons from recent developments in the IARC TP53 database. Hum Mutat 2007, 28:622-629. 10.1002/humu.20495, 17311302.
11. te Poele RH, Okorokov AL, Joel SP. RNA synthesis block by 5, 6-dichloro-1-beta-D-ribofuranosylbenzimidazole (DRB) triggers p53-dependent apoptosis in human colon carcinoma cells. Oncogene 1999, 18:5765-5772. 10.1038/sj.onc.1202961, 10523857.
12. Chang TC, Tsai LC, Hung MW, Chu LL, Chu JT, Chen YC. Effects of transcription and translation inhibitors on a human gastric carcinoma cell line. Potential role of Bcl-X(S) in apoptosis triggered by these inhibitors. Biochem Pharmacol 1997, 53:969-977. 10.1016/S0006-2952(96)00868-4, 9174110.
13. Koumenis C, Giaccia A. Transformed cells require continuous activity of RNA polymerase II to resist oncogene-induced apoptosis. Mol Cell Biol 1997, 17:7306-7316. 232587, 9372962.
14. Shapiro GI. Cyclin-dependent kinase pathways as targets for cancer treatment. J Clin Oncol 2006, 24:1770-1783. 10.1200/JCO.2005.03.7689, 16603719.
15. Fischer PM, Gianella-Borradori A. Recent progress in the discovery and development of cyclin-dependent kinase inhibitors. Expert Opin Investig Drugs 2005, 14:457-477. 10.1517/13543784.14.4.457, 15882121.
16. Basso AD, Doll RJ. Inhibition of cyclin-dependent kinases - a review of the recent patent literature. Recent Pat Anticancer Drug Discov 2006, 1(3):357-367. 18221046, 10.2174/157489206778776916.
17. Senderowicz AM. Inhibitors of cyclin-dependent kinase modulators for cancer therapy. Prog Drug Res 2005, 63:183-206. full_text, 16265881.
18. Yankulov K, Yamashita K, Roy R, Egly JM, Bentley DL. The transcriptional elongation inhibitor 5,6-dichloro-1-beta-D-ribofuranosylbenzimidazole inhibits transcription factor IIH-associated protein kinase. J Biol Chem 1995, 270:23922-23925. 10.1074/jbc.270.41.23922, 7592583.
19. Marshall NF, Price DH. Purification of P-TEFb, a transcription factor required for the transition into productive elongation. J Biol Chem 1995, 270:12335-12338. 10.1074/jbc.270.44.26303, 7759473.
20. Ljungman M, Zhang F, Chen F, Rainbow AJ, McKay BC. Inhibition of RNA polymerase II as a trigger for the p53 response. Oncogene 1999, 18:583-592. 10.1038/sj.onc.1202356, 9989808.
21. Dubois MF, Nguyen VT, Bellier S, Bensaude O. Inhibitors of transcription such as 5,6-dichloro-1-beta-D-ribofuranosylbenzimidazole and isoquinoline sulfonamide derivatives (H-8 and H-7) promote dephosphorylation of the carboxyl-terminal domain of RNA polymerase II largest subunit. J Biol Chem 1994, 269:13331-13336.
22. Shugar D. Development of inhibitors of protein kinases CKI and CKII and some related aspects, including donor and acceptor specificities and viral protein kinases. Cell Mol Biol Res 1994, 40:411-419.
23. Andera L, Wasylyk B. Transcription abnormalities potentiate apoptosis of normal human fibroblasts. Mol Med 1997, 3:852-863. 2230284, 9440118.
24. Lantelme E, Palermo B, Granziero L, Mantovani S, Campanelli R, Monafo V, Lanzavecchia A, Giachino C. Cutting edge: recombinase-activating gene expression and V(D)J recombination in CD4+CD3low mature T lymphocytes. J Immunol 2000, 164:3455-3459.
25. Rogakou EP, Pilch DR, Orr AH, Ivanova VS, Bonner WM. DNA double-stranded breaks induce histone H2AX phosphorylation on serine 139. J Biol Chem 1998, 273:5858-5868. 10.1074/jbc.273.10.5858, 9488723.
26. Rogakou EP, Nieves-Neira W, Boon C, Pommier Y, Bonner WM. Initiation of DNA fragmentation during apoptosis induces phosphorylation of H2AX histone at serine 139. J Biol Chem 2000, 275:9390-9395. 10.1074/jbc.275.13.9390, 10734083.
27. Banin S, Moyal L, Shieh S, Taya Y, Anderson CW, Chessa L, Smorodinsky NI, Prives C, Reiss Y, Shiloh Y, Ziv Y. Enhanced phosphorylation of p53 by ATM in response to DNA damage. Science 1998, 281:1674-1677. 10.1126/science.281.5383.1674, 9733514.
28. Wu X, Bayle JH, Olson D, Levine AJ. The p53-mdm-2 autoregulatory feedback loop. Genes Dev 1993, 7:1126-1132. 10.1101/gad.7.7a.1126, 8319905.
29. Chipuk JE, Kuwana T, Bouchier-Hayes L, Droin NM, Newmeyer DD, Schuler M, Green DR. Direct activation of Bax by p53 mediates mitochondrial membrane permeabilization and apoptosis. Science 2004, 303:1010-1014. 10.1126/science.1092734, 14963330.
30. Mihara M, Erster S, Zaika A, Petrenko O, Chittenden T, Pancoska P, Moll UM. p53 has a direct apoptogenic role at the mitochondria. Mol Cell 2003, 11:577-590. 10.1016/S1097-2765(03)00050-9, 12667443.
31. Komarov PG, Komarova EA, Kondratov RV, Christov-Tselkov K, Coon JS, Chernov MV, Gudkov AV. A chemical inhibitor of p53 that protects mice from the side effects of cancer therapy. Science 1999, 285:1733-1737. 10.1126/science.285.5434.1733, 10481009.
32. Strom E, Sathe S, Komarov PG, Chernova OB, Pavlovska I, Shyshynova I, Bosykh DA, Burdelya LG, Macklis RM, Skaliter R. Small-molecule inhibitor of p53 binding to mitochondria protects mice from gamma radiation. Nat Chem Biol 2006, 2:474-479. 10.1038/nchembio809, 16862141.
33. Porcedda P, Turinetto V, Lantelme E, Fontanella E, Chrzanowska K, Ragona R, De Marchi M, Delia D, Giachino C. Impaired elimination of DNA double-strand break-containing lymphocytes in ataxia telangiectasia and Nijmegen breakage syndrome. DNA Repair (Amst) 2006, 5:904-913. 10.1016/j.dnarep.2006.05.002, 16765653.
34. Cheng J, Haas M. Frequent mutations in the p53 tumor suppressor gene in human leukemia T-cell lines. Mol Cell Biol 1990, 10:5502-5509. 361264, 2144611.
35. Karpinich NO, Tafani M, Schneider T, Russo MA, Farber JL. The course of etoposide-induced apoptosis in Jurkat cells lacking p53 and Bax. J Cell Physiol 2006, 208:55-63. 10.1002/jcp.20638, 16547931.
36. Murray-Zmijewski F, Lane DP, Bourdon JC. p53/p63/p73 isoforms: an orchestra of isoforms to harmonise cell differentiation and response to stress. Cell Death Differ 2006, 13:962-972. 10.1038/sj.cdd.4401914, 16601753.
37. Zhao QL, Kondo T, Noda A, Fujiwara Y. Mitochondrial and intracellular free-calcium regulation of radiation-induced apoptosis in human leukemic cells. Int J Radiat Biol 1999, 75:493-504. 10.1080/095530099140429, 10331855.
38. Wolf D, Rotter V. Major deletions in the gene encoding the p53 tumor antigen cause lack of p53 expression in HL-60 cells. Proc Natl Acad Sci USA 1985, 82:790-794. 10.1073/pnas.82.3.790, 397132, 2858093.
39. Farrell PJ, Allan GJ, Shanahan F, Vousden KH, Crook T. p53 is frequently mutated in Burkitt's lymphoma cell lines. Embo J 1991, 10:2879-2887. 452998, 1915267.
40. Lacombe F, Durrieu F, Briais A, Dumain P, Belloc F, Bascans E, Reiffers J, Boisseau MR, Bernard P. Flow cytometry CD45 gating for immunophenotyping of acute myeloid leukemia. Leukemia 1997, 11:1878-1886. 10.1038/sj.leu.2400847, 9369421.
41. Karpova MB, Schoumans J, Ernberg I, Henter JI, Nordenskjold M, Fadeel B. Raji revisited: cytogenetics of the original Burkitt's lymphoma cell line. Leukemia 2005, 19:159-161.
42. Kuroki J, Hirokawa M, Kitabayashi A, Lee M, Horiuchi T, Kawabata Y, Miura AB. Cell-permeable ceramide inhibits the growth of B lymphoma Raji cells lacking TNF-alpha-receptors by inducing G0/G1 arrest but not apoptosis: a new model for dissecting cell-cycle arrest and apoptosis. Leukemia 1996, 10:1950-1958.
43. Kawabata Y, Hirokawa M, Kitabayashi A, Horiuchi T, Kuroki J, Miura AB. Defective apoptotic signal transduction pathway downstream of caspase-3 in human B-lymphoma cells: A novel mechanism of nuclear apoptosis resistance. Blood 1999, 94:3523-3530.
44. Casey G. The BRCA1 and BRCA2 breast cancer genes. Curr Opin Oncol 1997, 9:88-93. 10.1097/00001622-199701000-00014, 9090499.
45. Aaltonen LA, Peltomaki P. Genes involved in hereditary nonpolyposis colorectal carcinoma. Anticancer Res 1994, 14:1657-1660.
46. Froggatt NJ, Brassett C, Koch DJ, Evans DG, Hodgson SV, Ponder BA, Maher ER. Mutation screening of MSH2 and MLH1 mRNA in hereditary non-polyposis colon cancer syndrome. J Med Genet 1996, 33:726-730. 10.1136/jmg.33.9.726, 1050724, 8880570.
47. Matei IR, Guidos CJ, Danska JS. ATM-dependent DNA damage surveillance in T-cell development and leukemogenesis: the DSB connection. Immunol Rev 2006, 209:142-158. 10.1111/j.0105-2896.2006.00361.x, 16448540.
48. Wang S, Fischer PM. Cyclin-dependent kinase 9: a key transcriptional regulator and potential drug target in oncology, virology and cardiology. Trends Pharmacol Sci 2008, 29:302-313. 10.1016/j.tips.2008.03.003, 18423896.
49. Bible KC, Bible RH, Kottke TJ, Svingen PA, Xu K, Pang YP, Hajdu E, Kaufmann SH. Flavopiridol binds to duplex DNA. Cancer Res 2000, 60:2419-2428.
50. Cheok CF, Dey A, Lane DP. Cyclin-dependent kinase inhibitors sensitize tumor cells to nutlin-induced apoptosis: a potent drug combination. Mol Cancer Res 2007, 5:1133-1145. 10.1158/1541-7786.MCR-07-0161, 18025259.
51. Richon VM, Sandhoff TW, Rifkind RA, Marks PA. Histone deacetylase inhibitor selectively induces p21WAF1 expression and gene-associated histone acetylation. Proc Natl Acad Sci USA 2000, 97:10014-10019. 10.1073/pnas.180316197, 27656, 10954755.
52. Rosato RR, Almenara JA, Yu C, Grant S. Evidence of a functional role for p21WAF1/CIP1 down-regulation in synergistic antileukemic interactions between the histone deacetylase inhibitor sodium butyrate and flavopiridol. Mol Pharmacol 2004, 65:571-581. 10.1124/mol.65.3.571, 14978235.
53. Nguyen DM, Schrump WD, Chen GA, Tsai W, Nguyen P, Trepel JB, Schrump DS. Abrogation of p21 expression by flavopiridol enhances depsipeptide-mediated apoptosis in malignant pleural mesothelioma cells. Clin Cancer Res 2004, 10:1813-1825. 10.1158/1078-0432.CCR-0901-3, 15014036.
54. Arima Y, Nitta M, Kuninaka S, Zhang D, Fujiwara T, Taya Y, Nakao M, Saya H. Transcriptional blockade induces p53-dependent apoptosis associated with translocation of p53 to mitochondria. J Biol Chem 2005, 280:19166-19176. 10.1074/jbc.M410691200, 15753095.
55. Derheimer FA, O'Hagan HM, Krueger HM, Hanasoge S, Paulsen MT, Ljungman M. RPA and ATR link transcriptional stress to p53. Proc Natl Acad Sci USA 2007, 104:12778-12783. 10.1073/pnas.0705317104, 1937543, 17616578.
56. Ljungman M, O'Hagan HM, Paulsen MT. Induction of ser15 and lys382 modifications of p53 by blockage of transcription elongation. Oncogene 2001, 20:5964-5971. 10.1038/sj.onc.1204734, 11593403.
57. O'Hagan HM, Ljungman M. Phosphorylation and nuclear accumulation are distinct events contributing to the activation of p53. Mutat Res 2004, 546:7-15.
58. White E, Prives C. DNA damage enables p73. Nature 1999, 399:734-735. 10.1038/21539, 10391235.
59. Irwin MS, Kondo K, Marin MC, Cheng LS, Hahn WC, Kaelin WG. Chemosensitivity linked to p73 function. Cancer Cell 2003, 3:403-410. 10.1016/S1535-6108(03)00078-3, 12726865.
60. Sayan AE, Sayan BS, Gogvadze V, Dinsdale D, Nyman U, Hansen TM, Zhivotovsky B, Cohen GM, Knight RA, Melino G. P73 and caspase-cleaved p73 fragments localize to mitochondria and augment TRAIL-induced apoptosis. Oncogene 2008, 27:4363-4372. 10.1038/onc.2008.64, 18362891.
61. Okada H, Mak TW. Pathways of apoptotic and non-apoptotic death in tumour cells. Nat Rev Cancer 2004, 4:592-603. 10.1038/nrc1412, 15286739.